Renal sympathetic denervation for treatment of drug-resistant hypertension one-year results from the symplicity HTN-2 randomized, controlled trial

Murray D Esler, Henry Krum, Markus Peter Schlaich, Roland E Schmieder, Michael Bohm, Paul Sobotka

Research output: Contribution to journalArticleResearchpeer-review

396 Citations (Scopus)


Control patients who crossed over to renal denervation with the Symplicity system had a significant drop in blood pressure similar to that observed in patients receiving immediate denervation. Renal denervation provides safe and sustained reduction of blood pressure to 1 year.
Original languageEnglish
Pages (from-to)2976 - 2982
Number of pages7
Issue number25
Publication statusPublished - 2012

Cite this